AllSight
Companies · EXEL · Biological Products, (No Diagnostic Substances)

EXELIXIS, INC. (EXEL)

EXELIXIS, INC. (EXEL) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.

EXELIXIS, INC. (EXEL) stock — financials & valuation

Key numbers for EXELIXIS, INC. (EXEL): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.

AllSight quality score: 77/100 — a percentile rank of EXELIXIS, INC.’s fundamentals against Manufacturing peers, weakest on valuation. A quality ranking, not a price prediction.

Market cap$14.5B
P / E16.8×
P / S5.9×
EV / EBITDA13.9×
Gross margin96.5%
Operating margin39.9%
Net margin35.3%
Return on equity46.7%
ROIC51.7%
Revenue growth9.2%
Debt / equity0.0×
Dividend yield0.0%

Is EXELIXIS, INC. overvalued? P/E looks undervalued vs its 5-year range; P/S looks overvalued vs its 5-year range; EV/EBITDA looks fair vs its 5-year range; P/B looks overvalued vs its 5-year range.

Independent of the events above — derived from EXELIXIS, INC.’s own financial statements and shown as context, never as advice.

Sep 11, 2026FDA review delayed
Exelixis delays zanzalintinib FDA decision after major amendment
Aug 31, 2026Patent appeal affirmed
Exelixis wins MSN patent appeal, but a 2032 patent trial remains
Related companies in Biological Products, (No Diagnostic Substances)
Open live on AllSight — the whole market, decoded →

About AllSight · Editorial standards & method · Contact